Arrowhead Pharmaceuticals, Inc.

NasdaqGS:ARWR Stock Report

Market Cap: US$3.6b

Arrowhead Pharmaceuticals Future Growth

Future criteria checks 2/6

Arrowhead Pharmaceuticals is forecast to grow earnings and revenue by 21.8% and 32.9% per annum respectively. EPS is expected to grow by 26% per annum. Return on equity is forecast to be -111% in 3 years.

Key information

21.8%

Earnings growth rate

26.0%

EPS growth rate

Biotechs earnings growth20.6%
Revenue growth rate32.9%
Future return on equity-111.0%
Analyst coverage

Good

Last updated08 Mar 2024

Recent future growth updates

Recent updates

Shareholders May Be Wary Of Increasing Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation Package

Mar 08
Shareholders May Be Wary Of Increasing Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation Package

Estimating The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Feb 19
Estimating The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Arrowhead Pharmaceuticals: A Leading Small-Cap Developer Of RNAi Therapy

Jan 21

Pinning Down Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) P/S Is Difficult Right Now

Dec 25
Pinning Down Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) P/S Is Difficult Right Now

Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Debt In A Risky Way?

Sep 19
Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Debt In A Risky Way?

Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Climb 25% But Its Business Is Yet to Catch Up

Apr 17
Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Climb 25% But Its Business Is Yet to Catch Up

Shareholders May Be More Conservative With Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation For Now

Mar 10
Shareholders May Be More Conservative With Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation For Now

A Look At The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Jan 24
A Look At The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

We're Not Worried About Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Cash Burn

Oct 24
We're Not Worried About Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Cash Burn

Arrowhead Pharmaceuticals: Emerging From The 'Data Desert' With A Flood Of Opportunities

Sep 12

Johnson & Johnson And Arrowhead Pharmaceuticals Could Have Big News Coming

Aug 23

Arrowhead seeks New Zealand regulator nod to start trial of ARO-MMP7 for lung disease

Aug 17

Arrowhead Pharmaceuticals: An RNAi Name To Know

Jul 28

Arrowhead Pharmaceuticals names internal officer as new COO

Jul 20

Arrowhead begins dosing in early-stage studies of 2 potential lung disease drugs

Jul 05

Arrowhead Pharma: We Can Afford To Wait For More Proof

Jun 28

Companies Like Arrowhead Pharmaceuticals (NASDAQ:ARWR) Can Afford To Invest In Growth

Jun 18
Companies Like Arrowhead Pharmaceuticals (NASDAQ:ARWR) Can Afford To Invest In Growth

Arrowhead Pharma: Know Pros' Calcs For Coming Stock Prices

Apr 14

Are Investors Undervaluing Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) By 46%?

Feb 08
Are Investors Undervaluing Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) By 46%?

Arrowhead: 2021 Was A Struggle Valuation Wise - Things May Get Worse In 2022

Jan 26

Accumulate Arrowhead For Its RNAi Pipeline

Jan 17

Johnson & Johnson's JNJ-3989 News Could Propel Arrowhead Stock To New All-Time Highs

Nov 03

Are Investors Undervaluing Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) By 34%?

Oct 09
Are Investors Undervaluing Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) By 34%?

The Partnership Effect: Arrowhead Forges Its Future

Aug 27

Earnings and Revenue Growth Forecasts

NasdaqGS:ARWR - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
9/30/2026269-315-284-17710
9/30/2025181-300-255-20615
9/30/2024126-313-482-31615
12/31/2023182-297-403-196N/A
9/30/2023241-205-331-154N/A
6/30/2023256-181-343-197N/A
3/31/2023273-150-353-245N/A
12/31/2022278-155-236-150N/A
9/30/2022243-176-189-136N/A
6/30/2022250-154-120-91N/A
3/31/2022263-112-75-52N/A
12/31/2021144-183124149N/A
9/30/2021138-141148171N/A
6/30/2021108-126167184N/A
3/31/202189-110165181N/A
12/31/202080-103-123-111N/A
9/30/202088-85-108-96N/A
6/30/2020124-24-89-71N/A
3/31/202013910-46-27N/A
12/31/201916453-34-19N/A
9/30/201916968161173N/A
6/30/201913746152157N/A
3/31/20199510130132N/A
12/31/201847-29134136N/A
9/30/201816-54-49-47N/A
6/30/201814-54-55-54N/A
3/31/201822-44-52-50N/A
12/31/201731-35-51-49N/A
9/30/201731-34N/A-24N/A
6/30/201723-46N/A-25N/A
3/31/201713-60N/A-33N/A
12/31/20164-75N/A-33N/A
9/30/20160-82N/A-64N/A
6/30/20160-84N/A-66N/A
3/31/20160-81N/A-61N/A
12/31/20150-89N/A-63N/A
9/30/20150-92N/A-66N/A
6/30/20150-90N/A-65N/A
3/31/20150-85N/A-61N/A
12/31/20140-71N/A-53N/A
9/30/20140-59N/A-35N/A
6/30/20140-50N/A-30N/A
3/31/20140-44N/A-25N/A
12/31/20130-37N/A-22N/A
9/30/20130-31N/A-19N/A
6/30/20130-23N/A-18N/A
3/31/20130-25N/A-17N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ARWR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ARWR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ARWR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ARWR's revenue (32.9% per year) is forecast to grow faster than the US market (8.2% per year).

High Growth Revenue: ARWR's revenue (32.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ARWR is forecast to be unprofitable in 3 years.


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.